Back to Research Home
BRKRBruker Corporation
Industrials · Biotechnology: Laboratory Analytical Instruments · Mid
$57.59+0.49%
As of 23 Oct 2026Mkt cap $9.0B
Stage 13
AVOID
Fundamentals
24.2/75
Technical
8.0/15
Independent
32.3/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- −10.0%
- 3M
- −4.1%
- 6M
- +57.6%
- 1Y
- +47.9%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —Hist median 45.4x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- —
- Operating margin
- 7.5%
- FCF margin
- 1.3%
- Current ratio
- 1.7x
Growth
- Revenue growth
- +2.1%Latest FY YoY
- Revenue CAGR
- +9.2%
- EPS CAGR
- —
- FCF CAGR
- −30.9%
Capital
- Share-count trend
- +1.6%3Y annualised
- Net debt
- $1.7B12.9x OCF
Annual trend
- CAGR 2021–2025
- +9.2%
- Latest · 2025
- $3B
- YoY
- +2.1%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- headwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded